NASDAQ:ENTA
Enanta Pharmaceuticals Stock News
$15.17
+1.26 (+9.06%)
At Close: May 03, 2024
Enanta Pharmaceuticals Announces Data Presentations at AASLD's The Liver Meeting® 2021
07:00am, Friday, 01'st Oct 2021
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Data Presentations at AASLD's The Liver Meeting® 2021
Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors
07:00am, Monday, 23'rd Aug 2021
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors
Enanta Pharmaceuticals, Inc.'s (ENTA) CEO Jay Luly on Q3 2021 Results - Earnings Call Transcript
12:37pm, Sunday, 08'th Aug 2021
Enanta Pharmaceuticals, Inc.'s (ENTA) CEO Jay Luly on Q3 2021 Results - Earnings Call Transcript
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Misses Revenue Estimates
07:46pm, Thursday, 05'th Aug 2021
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 15.60% and -1.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Webcast and Conference Call Today at 4:30 p.m. ET
Enanta Pharmaceuticals Announces the Planned Retirement of Chief Medical Officer Nathalie Adda, M.D.
05:30pm, Wednesday, 14'th Jul 2021
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces the Planned Retirement of Chief Medical Officer Nathalie Adda, M.D.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Presents New Data for EDP-721, an Oral HBV RNA Destabilizer, at the International Liver Congress (EASL)
Enanta Pharmaceuticals, Inc.'s (ENTA) CEO Jay Luly on Q2 2021 Results - Earnings Call Transcript
01:39am, Monday, 10'th May 2021
Enanta Pharmaceuticals, Inc.'s (ENTA) CEO Jay Luly on Q2 2021 Results - Earnings Call Transcript
Enanta's EDP-514 Four-Week Treatment Shows Around 10 Time Reduction In Hepatitis B Virus RNA
09:58am, Friday, 07'th May 2021
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has announced data from the first two dose cohorts of Part 2 of its Phase 1b study evaluating EDP-514 in chronic hepatitis B virus (HBV) patients already
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
06:47pm, Thursday, 06'th May 2021
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -15.96% and -21.35%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stoc
Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for
01:49pm, Wednesday, 28'th Apr 2021
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Bottom Fishing Club: Enanta Pharmaceuticals
05:13am, Monday, 08'th Mar 2021
Enanta's huge cash holdings are very desirable in an uncertain economic world and overvalued U.S. stock market setup. The drug trial pipeline could have several positive news developments in the comin
Enanta Pharmaceuticals to Present at Upcoming Investor Conferences
07:01am, Tuesday, 02'nd Mar 2021
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at Upcoming Investor Conferences
Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q1 2021 Results - Earnings Call Transcript
10:20pm, Monday, 08'th Feb 2021
Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q1 2021 Results - Earnings Call Transcript
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
06:12pm, Monday, 08'th Feb 2021
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 50.00% and 19.26%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the sto
